We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory... Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA and other regions, of which a majority of revenue is derived from the United States. Show more
RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of...
RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the...
RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its...
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.2653 | -11.2318358144 | 11.2653 | 11.37 | 9.96 | 1023167 | 10.76215578 | CS |
4 | -1.63 | -14.0154772141 | 11.63 | 11.69 | 9.96 | 1152596 | 10.61229406 | CS |
12 | -3.11 | -23.7223493516 | 13.11 | 13.52 | 9.96 | 1288290 | 11.07842001 | CS |
26 | -6.7 | -40.119760479 | 16.7 | 17.755 | 9.96 | 970098 | 12.41224846 | CS |
52 | -4.47 | -30.8914996545 | 14.47 | 19.8702 | 9.96 | 764630 | 14.01593566 | CS |
156 | -29.09 | -74.4180097212 | 39.09 | 40.65 | 9.96 | 847137 | 18.35295403 | CS |
260 | -25.01 | -71.4367323622 | 35.01 | 45.48 | 9.96 | 811323 | 21.20466349 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions